Skip Nav Destination
Close Modal
Search Results for
gastrointestinal-cancers
Update search
Filter
All
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-20 of 976 Search Results for
gastrointestinal-cancers
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.0860.2021.
Published: 02 May 2022
.... Schwarz1,3,7 1 Department of Surgery, Indiana University School of Medicine, South Bend, IN 2 Department of Pediatrics, Indiana University School of Medicine, South Bend, IN 3 Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 4 Department of Gastrointestinal Surgery, The Seventh...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 751–761.
Published: 04 May 2022
... outside of breast cancer, we analyzed tucatinib response in upper gastrointestinal cancer cell lines with and without HER2 amplification, and observed a similar robust association between activated HER2 signaling and tucatinib response ( Fig. 1I and Supplementary Table S8). Of the 21 gastric cancer cell...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.0087.2022.
Published: 11 May 2022
..., Houston, TX 77030 4Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 Running title: Novel...
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 810–820.
Published: 04 May 2022
..., justifying use of daily dosing. Overall, we report that RRSP-DTB strongly regresses hard-to-treat KRAS-mutant PDX models of pancreatic cancer, warranting further development of this pan-RAS biologic for the management of RAS-addicted tumors. Note: Supplementary data...
Includes: Supplementary data
Images
in 89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model
> Molecular Cancer Therapeutics
Published: 01 April 2022
Figure 3. 89Zr-DFO-Rit-mIFNα immunoPET shows therapeutic efficacy in lymphoma-bearing mice. C3H mice bearing subcutaneous B-cell lymphoma (38C13-hCD20) tumors were injected with low-dose (2.2 MBq/10 μg) 89Zr-DFO-Rit-mIFNα ( A ); therapeutic dose (2.2 MBq/50 μg) 89Zr-DFO-Rit-mIFNα ( B ); low dose (2.2 MBq/10 μg) control 89Zr-DFO-Rit ( C ). Shown are coronal and sagittal whole-body MIP immunoPET/CT overlays acquired 4, 24, and 75 hours p.i. T = tumors, indicated white arrow, L = liver, GI = gastrointestinal tract, H = heart, white arrow = tumor-infiltrated lymph nodes. Figure 3. 89Zr-DFO-Rit-mIFNα immunoPET shows therapeutic efficacy in lymphoma-bearing mice. C3H mice bearing subcutaneous B-cell lymphoma (38C13-hCD20) tumors were injected with low-dose (2.2 MBq/10 μg) 89Zr-DFO-Rit-mIFNα (A); therapeutic dose (2.2 MBq/50 μg) 89Zr-DFO-Rit-mIFNα (B); low dose (2.2 MBq/10 μg) control 89Zr-DFO-Rit (C). Shown are coronal and sagittal whole-body MIP immunoPET/CT overlays acquired 4, 24, and 75 hours p.i. T = tumors, indicated white arrow, L = liver, GI = gastrointestinal tract, H = heart, white arrow = tumor-infiltrated lymph nodes. More
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 607–615.
Published: 01 April 2022
...) 89Zr-DFO-Rit-mIFNα ( B ); low dose (2.2 MBq/10 μg) control 89Zr-DFO-Rit ( C ). Shown are coronal and sagittal whole-body MIP immunoPET/CT overlays acquired 4, 24, and 75 hours p.i. T = tumors, indicated white arrow, L = liver, GI = gastrointestinal tract, H = heart, white arrow = tumor...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.0802.2021.
Published: 11 April 2022
... metastatic 575 pancreatic adenocarcinoma (mPDAC). In: Journal of Clinical Oncology. Vol. 39. ASCO 2021 576 Annual Meeting: Gastrointestinal Cancers Symposium, Virtual conference; 2020. pp. 404 404. 577 39. Li G, Bethune MT, Wong S, Joglekar A V., Leonard MT, Wang JK, Kim JT, Cheng D, Peng 578 S, Zaretsky JM...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.0950.2021.
Published: 12 April 2022
...Jacob J. Adashek; Arjun K. Menta; Neha K. Reddy; Aakash P. Desai; Jason Roszik; Vivek Subbiah BRAF plus MEK inhibitor combinations are currently FDA approved for melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 686–699.
Published: 01 April 2022
... nephrotoxicity, in future applications of STxB as therapeutical “ferry” for tumor targeting. Human colorectal cancers and their metastasis express Gb3, allowing staining with a Shiga toxin–based fluorophore ( 2 ). Gb3 positivity in gastrointestinal carcinoma may be a potentially...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (1): 227–236.
Published: 07 January 2022
... ), the roles that DDR genes such as ARID1A, ATM, and PTEN play in gastrointestinal cancer progression currently needs further review ( 50–53 ). By better elucidating the HR-DDR genes relevant in gastroesophageal cancers, it would be possible to develop a validated HR-DDR assay...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 635–646.
Published: 01 April 2022
... in gastrointestinal stromal tumors, with DS-6157a, a first-in-class antibody-drug conjugate . Cancer Discov 2021 ; 11 : 1508 – 23 . 30.
Okajima
D
,
Yasuda
S
,
Maejima
T
,
Karibe
T
,
Sakurai
K
,
Aida
T
,
. Datopotamab deruxtecan, a novel TROP2-directed antibody...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.MCT-21-0599-A.2021.
Published: 01 April 2022
... T cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers. Clinical Cancer Research. 2020;26:2188 202. 31. Giordano G, Parcesepe P, D Andrea MR, Coppola L, Raimo TD, Remo A, et al. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.0623.2021.
Published: 21 March 2022
... of Wnt/beta-catenin signaling in 561 gastrointestinal cancers. Gastroenterology. 2012;142(2):219-32. 562 8. Nusse R, Clevers H. Wnt/beta-Catenin Signaling, Disease, and Emerging Therapeutic 563 Modalities. Cell. 2017;169(6):985-99. 564 9. Aguilera KY, Dawson DW. WNT Ligand Dependencies in Pancreatic...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P032.
Published: 01 December 2021
... of DNA damage repair (DDR). In preclinical studies, topoisomerase 1 inhibitors and ATR inhibitors demonstrate synergy in TP53 mutant gastrointestinal cancer cell lines. Based on the dearth of active later-line treatments in patients with advanced gastric/GEJ adenocarcinoma, we initiated a combinatorial...
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (2): 371–381.
Published: 08 February 2022
... to enhance the effects of immune checkpoint blockade in multiple tumor types. Although ovarian cancer is known to be radiosensitive, the use of abdominopelvic radiotherapy in metastatic peritoneal disease is limited by gastrointestinal and hematopoietic toxicities ( 9–14 ). Over the past decade, major...
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (3): 397–406.
Published: 04 March 2022
... P. Schiemann; S. Gail Eckhardt; Xuedong Liu; Anthony D. Piscopio Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. Although HDAC inhibitors are active in T-cell lymphomas, poor isoform selectivity, narrow...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (3): 427–439.
Published: 04 March 2022
... carcinomatosis of gastrointestinal and pancreatic cancers .
Cancer Res 2019 ; 79 : 3273 . 30.
Siddiqui
I
,
Schaeuble
K
,
Chennupati
V
,
Fuertes Marraco
SA
,
Calderon-Copete
S
,
Pais Ferreira
D
,
. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (2): 382–394.
Published: 08 February 2022
... to chemotherapeutic agents, with a fatality rate that is the highest among all types of thyroid cancer after anaplastic thyroid cancer. Our previous study on the genomic landscape of HCCs identified a high incidence of disruptions of mTOR pathway effectors. Here, we report a detailed analysis of mTOR signaling...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (2): 245–256.
Published: 08 February 2022
...://synergyfinder.fimm.fi ) using the Zero interaction potency (ZIP) model ( 32 ). Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). Ataxia telangiectasia and Rad3-related (ATR) kinase is an important therapeutic target due...
Includes: Supplementary data
Journal Articles
Journal:
Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P136.
Published: 01 December 2021
...Sarah Cohen-Gogo; Nisha Kanwar; Furqan Shaikh; Reto M. Baertschiger; Adam Shlien; David Malkin; Juan Putra; Ailish Coblentz; Anita Villani; Abha A. Gupta; Daniel A. Morgenstern Introduction Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the gastrointestinal tract...
